QHSLab Q3: Going Concern Reaffirmed as Cash Falls to $190K and Revenue Slips 8%
USAQ has more than doubled off its 52-week low of $0.08 on elevated volume (3.4× avg).
Summary
QHSLab's Q3 2026 10-Q reaffirms substantial doubt about its ability to continue as a going concern, with cash down to $190,464 and Q3 revenue off 8.1% year-over-year despite 13.4% nine-month growth.
Key Events · Earnings and Guidance · USAQ
-
Going Concern Warning Reaffirmed
Management states its history of losses and revenue level raise substantial doubt about the ability to continue as a going concern, citing a $4,022,572 accumulated deficit and a $119,021 net loss for the nine months ended September 30, 2026.
-
Cash Burn Leaves Thin Cushion
Cash and equivalents fell to $190,464 from $636,157 at December 31, 2025 — a $445,693 decline — after $334,989 used in operating activities and $110,704 for debt repayment.
-
Q3 Revenue Declines 8.1%
Third-quarter revenue was $677,172 versus $737,066 a year earlier, driven by a 37.0% drop in combined allergy diagnostics and immunotherapy revenue, partly offset by a 17.4% rise in Integrated Service Program revenue.
-
Q3 Swings to Net Loss
The quarter produced a net loss of $53,145 versus net income of $33,411 in Q3 2025, as G&A rose 86.2% to $244,705 and sales/marketing rose to $141,060.
Analysis · USAQ · Industrial Applications And Services
The going concern warning remains front and center in QHSLab's third-quarter report. Operating cash burn through nine months reached $334,989, leaving just $190,464 on hand against a $4.02 million accumulated deficit. Revenue for the nine months actually grew 13.4% to $2.25 million on the strength of the Integrated Service Program, but the third quarter itself shrank 8.1% year-over-year as allergy diagnostic and immunotherapy sales fell. Heavier sales/marketing and G&A spending pushed the quarter to a $53,145 net loss versus a $33,411 profit a year ago. Management also disclosed that disclosure controls and procedures were ineffective. With no debt maturities left but a thin cash cushion, new equity or debt financing will likely be needed — dilution risk for existing holders — unless collections and cost cuts close the gap.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, USAQ was trading at $0.37 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.08 to $1.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.